Our firm represents some of the world’s leading pharmaceutical, medical device, other life sciences and consumer products companies in their most significant mass tort and product liability litigation.
Our lawyers have decades of experience resolving these cases. By strategically charting a path to victory at the outset, our trial lawyers achieve excellent outcomes for our clients. We love to try cases and have helped our clients secure jury verdicts in their favor in state and federal courts throughout the country. But we also win complex mass torts and product liability litigations short of trial by exposing claims based on pseudo-science by filing Daubert and Frye motions (and other analogous state law motions), conducting pretrial evidentiary hearings, and filing motions for summary judgment. Because we present a credible trial threat, and because our focus on the science and facts raises the stakes for plaintiffs’ firms, we produce better settlements.
Our appellate lawyers have also won landmark life science and product liability cases in state and federal appellate courts—including in the U.S. Supreme Court—on significant tort law issues.
Our attorneys are widely regarded as some of the premier products liability attorneys in the United States and have been recognized repeatedly as the “go to” lawyers by numerous legal publications, including Chambers USA, The National Law Journal, Law360, The International Who’s Who of Product Liability Defence Lawyers, The Best Lawyers in America, Fortune, and Crain’s New York Business.
Representative Current Life Science Clients
- Forest Laboratories
- Colgate-Palmolive Company
- We serve as trial counsel for Colgate-Palmolive Company in cases venued throughout the country in which individuals claim to have contracted asbestos-related diseases from consumer use of cosmetic talcum powders allegedly tainted with asbestos formerly manufactured by our client. Since QE became involved in these cases, through an aggressive and focused litigation strategy, we have obtained dismissals in many cases and have recently achieved a string of significant victories at the pretrial, trial, post-trial and appellate stages of the litigation:
- QE obtained summary judgment victories in Pennsylvania, California, Maryland, New York and Wisconsin courts, and in federal district court in Georgia. QE successfully defended three straight challenges to those summary judgment victories.
- QE has also successfully moved, in multiple jurisdictions, to exclude testimony from experts who claimed to have found asbestos in our client’s talcum powder products, by demonstrating that those experts employed flawed microscopy techniques. Courts that have granted such motions include Pennsylvania, California, New York, Maryland, and federal district courts in Georgia and the District of Columbia.
- QE and co-counsel recently obtained a complete defense verdict for Colgate following a jury trial. QE previously tried three cases to jury verdict in Los Angeles, and we obtained complete defense verdicts in all three of those cases as well. After each verdict, the jurors have credited the strength and credibility of the defense experts, and Quinn Emanuel’s cross-examinations that exposed the analytical gaps in Plaintiff’s theories of product defect and causation.
- Lexapro® and Celexa® We are national counsel and trial counsel for Forest Laboratories, LLC, a subsidiary of Allergan, in cases filed in state and federal courts around the country in which plaintiffs claim that their ingestion during pregnancy of Celexa® or Lexapro®—prescription antidepressants sold by Forest—allegedly caused various birth defects in their children. We also represent the company in litigations in which plaintiffs allege Lexapro ingested during pregnancy causes autism.
- We represented EOS Products, LLC in a series of consumer class actions alleging that consumers were experiencing severe allergic reactions to the globally popular EOS lip balms, including a class action in the Central District of California brought by famed U.S. lawyer Mark Geragos. The sensationalistic allegations were headline news in the US on televisions shows such as Good Morning America, Today, and TMZ, and the litigation was featured on numerous popular media outlets. Ten follow-on class actions were soon filed in seven states by other plaintiffs’ attorneys. Within days of the filing of the first suit, we negotiated a very favorable settlement that included the public relations coup of return media appearances by Geragos lauding the company's response and extolling the product. This quick, creative, and effective resolution halted—and reversed—what could have been a product-crippling media onslaught.
- We obtained a 6-2 win in the U.S. Supreme Court for Wyeth in Bruesewitz v. Wyeth, 131 S. Ct. 1068 (2011), which held that the National Childhood Vaccine Injury Act expressly preempts state-law design-defect claims against manufacturers of childhood vaccines.